Headquartered in Memphis, Tennessee, Accredo Health Group, Inc., provides specialty pharmacy and related services for patients with certain complex and chronic conditions through our unique Therapeutic Resource Centers. 

 

Accredo’s Therapeutic Resource Centers are segmented by therapy and provide targeted therapy management programs for the following therapeutic areas: 

 

• Rheumatoid arthritis 

• Multiple sclerosis 

• Oncology 

• Hepatitis C 

• Immune disorders 

• Pulmonary arterial hypertension 

• Hemophilia 

• Other specialty therapies with dedicated care teams (RSV, growth deficiencies, etc.) 

 

Our services cover the range of needs posed by specialty pharmacy care. Our pharmacists and other healthcare professionals talk frequently with patients over the phone, helping them follow their treatment and educating them about their condition. And our reimbursement specialists provide benefits research services, with an explanation to the patient or patient’s caregiver of any financial responsibility he/she may have plus prior authorization determination. 

 

Accredo has adopted the Code of Ethics for Pharmacists created in 1994 by the American Pharmacists Association (APhA), which specifies ethics for all employed pharmacists. Accredo has also accepted the Principles of Practice for Pharmaceutical Care as adopted by the APhA Board of Trustees in 1995. These ethics and principles act as a framework for the ongoing evolution of our pharmacy practice. 

 

In the early 1980s, Le Bonheur Children's Medical Center in Memphis formed several healthcare companies to distribute clotting factor and Protropin® throughout the Southeast. Southern Health Systems, Inc., was formed in 1983 and, in 1990, Nova Factor, Inc. (NFI), was created as a wholly owned subsidiary of SHS.

 

Accredo Health, Incorporated, was organized in 1996 and acquired SHS and NFI In 1997, seeking additional growth within the specialty market, Accredo acquired Hemophilia Health Services, Inc., which had originally been started by a mother in response to her son's hemophilia.

 

Accredo became a publicly traded company in 1999. That same year, Hemophilia Health Services acquired Sunrise Health Management and entered the IVIG market. Other acquisitions soon followed, including Pharmacare Resources, Inc., and BioPartners in Care, Inc., in 2001. Accredo acquired the Specialty Pharmaceutical Services divisions and Clinical Business Solutions (now known as Proherant Health, Inc.) from Gentiva Health Services, Inc., in 2002. One of the newly acquired Gentiva divisions was renamed Accredo Therapeutics, Inc. (ATX), to focus on immunoglobulin and PAH therapies.

 

During this period, Accredo Health, Inc., continued to expand its role in the specialty pharmacy industry, and it was soon dispensing an elite array of biopharmaceuticals: Ceredase®, Cerezyme®, Avonex®, Synagis®, Tracleer®, Orfadin®, Actimmune®, Adagen®, Enbrel®, Flolan®, Remodulin®, Xolair®, Raptiva®, Aldurazyme®, Fabrazyme®, Aralast®, Zemaira®, and Apokyn®. In 2003, ATX was awarded accreditation by the Joint Commission on the Accreditation of Healthcare Organizations (JCAHO). That year, Accredo acquired Alpha Therapeutics Services. Home HealthCare Resources, Inc., Hemophilia Resources of America, Inc., and the pharmacy division of Pediatric Services of America, Inc., soon became part of our company.

 

ATX was renamed Accredo Health Group, Inc. (AHG), and, in January 2006, Hemophilia Health Services and Nova Factor were merged into Accredo Health Group, Inc., to make it easier for the healthcare community to recognize our name and to access all our services.
 

In 2004, Medco Health Solutions, Inc., (newly independent from Merck) and Accredo Health, Inc., announced a strategic alliance for specialty pharmacy. Accredo Health, Inc. became a wholly owned subsidiary of Medco on August 18, 2005.

 

Other subsidiaries of Accredo Health Group, Inc., include NutrePletion Resources, Critical Care Systems, and ActiveCare Network. 
 

Accredo continues to expand its position in the specialty pharmacy industry. Starting with a directed focus on rare diseases with only 22 specialty medications in its portfolio, Accredo now dispenses close to 200 specialty drugs from approximately 83 dispensing pharmacies nationwide.